Akros Pharma

Executive Summary

Akros Pharma Inc., a San Diego-based subsidiary of Shionogi & Co., Ltd., is a small, dynamic company dedicated to developing innovative small-molecule pharmaceutical products for the US and global markets. Founded in 2016, Akros leverages Shionogi's robust drug discovery and development capabilities to advance a pipeline focused on therapeutic areas such as infectious diseases, central nervous system disorders, and metabolic conditions. While the company operates as a private entity with limited public financial disclosure, its strategic alignment with Shionogi provides access to significant R&D resources and a proven track record in bringing drugs to market. Akros's role as a US clinical and regulatory hub positions it to support key milestones for Shionogi's pipeline, including potential New Drug Applications and pivotal trial data readouts. However, the lack of detailed pipeline visibility and standalone financials introduces uncertainty, and the company's success is heavily dependent on Shionogi's broader strategic decisions. Overall, Akros represents a focused, resource-backed player in the small-molecule space, but its standalone risk profile remains moderate due to its subsidiary status and limited public information.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 Trial for Novel Antibiotic Candidate60% success
• Q2 2027Regulatory Filing for CNS Drug in Japan (Shionogi-led) with US Implications70% success
• Q3 2026Presentation of Phase 2 Data for Metabolic Disorder Candidate50% success